BIOPREPARATIONS USING IN THE ISCHEMIC HEART INJURY THERAPY

Abstract

Possibility of biologically active substances using such as growth factors, cytomedines, natural antioxidants, substances contained in extracts from juvenile and fetal organs and animal tissues in the experiments and clinic of ischemic heart injury are discussed. Along with the well-studied and widely used in clinical practice biopreparations such as kordialin, actovegin, erbisol nesiritide, energostim, as promising tools for treatment of cardiovascular diseases, the extracts from the heart and low molecular weight fraction of cord blood are considered. It is shown that using of tissue reparative embriofetoplatsenta complex increases myocardial contractility. The main difference between these biopreparations and biogenic stimulants is that they have a balanced composition of biologically active substances, in particular different activators of regeneration and differentiation (fibroblast growth factors, nerve-stimulating factor and macrophage erythroid colonies) and anti-proliferative cytokines preventing cellular and systemic hyperstimulation as well as other substances able to initiate a directed differentiation of stem cells and to affect regeneration of human myocardium, and hence to optimize the treatment of myocardial infarction. In addition, fetal cells and their associates are almost nonimmunogens. Thus, if the growth factors and differentiation capable to regulate the mitotic activity of cardiomyocytes are determined, it will be possible to initiate a process of stem cells directed differentiation and affect on the human myocardium regeneration, and hence to optimize the treatment of myocardial infarction.

Keywords

• myocardial infarction
• biologically active substances
• growth factors
• cytomedines
• antioxidants
• extracts from heart
• cord blood
• fetal tissues